Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
- Zeteo Biomedical revealed today that it has been granted new patents in both the U.S. and the EU, recognizing its innovative drug delivery technology.
- The patents enhance Zeteo's exclusive ZTech platform lineup, which is designed to administer medications and biological treatments through nasal, eye, and under-the-tongue delivery methods.
- The patented delivery systems include single-use and multi-dose handheld devices that function reliably in various environments, including space-based microgravity.
- Timothy Sullivan, CEO of Zeteo, noted a growing worldwide interest in user-friendly, small-sized metered-dose products designed for nasal, eye, and sublingual administration that patients can easily use on their own.
- These innovations could accelerate development of patient-centric drug/device products and open new markets in terrestrial and interstellar healthcare.
13 Articles
13 Articles

Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled…
Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations - Send2Press Newswire
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled "Cartridge Devices for Administration of a Medicament" (U.S. Patent No. 12329949) and "Hand-Operated Devices for Administration of a Medicament" (EU Patent No. 3946526), further st…
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium